Eli Lilly and Co on Tuesday cut its annual profit forecast for the third time, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.
The company now expects adjusted full-year earnings of $7.70 to $7.85 per share, compared to its prior forecast of $7.90 to $8.05.
The drugmaker said it took an additional $300 million hit from the stronger dollar.
Multinational companies such as Abbott Laboratories and Johnson & Johnson have been hit by the dollar's strength against a basket of currencies.
Sales of Mounjaro, Lilly's newly-approved diabetes drug, was $187.3 million, with over half coming from the United States
https://finance.yahoo.com/news/1-eli-lilly-cuts-annual-104521448.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.